Cytosorbents Cor (CTSOD) 8.3000 $CTSOD
CytoSorbents Submits IDE Application to FDA for U.S. CytoSorb® Cardiac Surgery Trial
PR Newswire - Tue Dec 30, 6:15AM CST
CytoSorbents Corporation (NASDAQ CM: CTSO), a critical care immunotherapy company commercializing its CytoSorb® extracorporeal cytokine adsorber to reduce deadly inflammation in critically-ill and cardiac surgery patients, announced today that it has submitted an Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administration (FDA) to conduct its proposed clinical trial using CytoSorb® intra-operatively in patients undergoing complex cardiac surgery requiring the use of a heart-lung machine. The goal of CytoSorb® treatment is to reduce inflammatory mediators and proteins such as cytokines and plasma free hemoglobin generated during surgery that can lead to serious post-operative complications.
CTSO: 8.20 (+0.18)
CytoSorbents Corporation Begins NASDAQ Trading Today
PR Newswire - Tue Dec 23, 6:00AM CST
CytoSorbents Corporation (NASDAQ CM: CTSO), a critical care immunotherapy company commercializing its CytoSorb® extracorporeal cytokine adsorber to reduce deadly inflammation in critically-ill and cardiac surgery patients, announced that it will commence trading today on The Nasdaq Capital Market under its current ticker symbol "CTSO".
CTSO: 8.20 (+0.18)
CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development
PR Newswire - Mon Dec 22, 6:00AM CST
CytoSorbents Corporation (OTCQB:CTSOD), a critical care focused immunotherapy company marketing its CytoSorb® blood purification technology to help fight deadly inflammation in critically-ill and cardiac surgery patients in 28 countries worldwide, today announced the appointment of Dr. Gregory B. Di Russo, MD, FACS, as its Senior Vice President of Clinical Development, effective January 5, 2015.
CTSO: 8.20 (+0.18)
CytoSorbents Receives NASDAQ Listing Approval
PR Newswire - Thu Dec 18, 6:00AM CST
CytoSorbents Corporation (OTCQB: CTSOD), a critical care immunotherapy company commercializing its CytoSorb® extracorporeal cytokine adsorber to reduce deadly inflammation in critically-ill and cardiac surgery patients, announced today that its common stock has been approved for listing on The Nasdaq Capital Market. Shares are expected to begin trading on The Nasdaq Capital Market on Tuesday, December 23, 2014 under the ticker symbol "CTSO".
CTSO: 8.20 (+0.18)
CytoSorbents Announces Strategic Partnership with Fresenius Medical Care
PR Newswire Europe - Tue Dec 16, 2:28AM CST
CytoSorbents Corporation (OTCQB: CTSOD), a leader in critical care immunotherapy and blood purification, announced yesterday that they have entered into a multi-country strategic partnership with Fresenius Medical Care AG & CO KGaA to commercialize CytoSorbents' CytoSorb(R) therapy.
Recent CytoSorb® Case Reports Highlight its Use to Help Save the Lives of Critically-Ill Patients
PR Newswire - Wed Dec 10, 8:25AM CST
CytoSorbents Corporation (OTCQB: CTSO) trading under stock ticker symbol CTSOD, a critical care immunotherapy company commercializing its CytoSorb® cytokine adsorber to treat deadly inflammation in critically-ill patients, highlights recent treatment successes published in peer-reviewed journal articles.
CTSO: 8.20 (+0.18)
/C O R R E C T I O N -- CytoSorbents Corporation/
PR Newswire - Fri Dec 05, 2:37PM CST
In the news release, "CytoSorbents Teams with Smart Medical Solutions to Distribute CytoSorb in Romania and Moldova", issued 05-Dec-2014 by CytoSorbents Corporation over PR Newswire, we are advised by the Company that the common stock trading symbol of CytoSorbents Corporation has temporarily changed for the next 20 trading days to "CTSOD" to reflect the reverse split of the Company's common shares that became effective on December 4, 2014, after which it will revert back to "CTSO". The new CUSIP number is 23283X 206. The shares will continue to trade on the OTCQB, although the Company has disclosed that it has filed an application to up-list to the NASDAQ Capital Markets which is pending final evaluation. According to the Company, there can be no assurances that NASDAQ will approve this application. The complete, corrected release follows:
CTSO: 8.20 (+0.18)
CytoSorbents Submits IDE Application to FDA for U.S. CytoSorb® Cardiac Surgery Trial
PR Newswire - Tue Dec 30, 6:15AM CST
CytoSorbents Corporation (NASDAQ CM: CTSO), a critical care immunotherapy company commercializing its CytoSorb® extracorporeal cytokine adsorber to reduce deadly inflammation in critically-ill and cardiac surgery patients, announced today that it has submitted an Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administration (FDA) to conduct its proposed clinical trial using CytoSorb® intra-operatively in patients undergoing complex cardiac surgery requiring the use of a heart-lung machine. The goal of CytoSorb® treatment is to reduce inflammatory mediators and proteins such as cytokines and plasma free hemoglobin generated during surgery that can lead to serious post-operative complications.
CTSO: 8.20 (+0.18)
CytoSorbents Corporation Begins NASDAQ Trading Today
PR Newswire - Tue Dec 23, 6:00AM CST
CytoSorbents Corporation (NASDAQ CM: CTSO), a critical care immunotherapy company commercializing its CytoSorb® extracorporeal cytokine adsorber to reduce deadly inflammation in critically-ill and cardiac surgery patients, announced that it will commence trading today on The Nasdaq Capital Market under its current ticker symbol "CTSO".
CTSO: 8.20 (+0.18)
CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development
PR Newswire - Mon Dec 22, 6:00AM CST
CytoSorbents Corporation (OTCQB:CTSOD), a critical care focused immunotherapy company marketing its CytoSorb® blood purification technology to help fight deadly inflammation in critically-ill and cardiac surgery patients in 28 countries worldwide, today announced the appointment of Dr. Gregory B. Di Russo, MD, FACS, as its Senior Vice President of Clinical Development, effective January 5, 2015.
CTSO: 8.20 (+0.18)
CytoSorbents Receives NASDAQ Listing Approval
PR Newswire - Thu Dec 18, 6:00AM CST
CytoSorbents Corporation (OTCQB: CTSOD), a critical care immunotherapy company commercializing its CytoSorb® extracorporeal cytokine adsorber to reduce deadly inflammation in critically-ill and cardiac surgery patients, announced today that its common stock has been approved for listing on The Nasdaq Capital Market. Shares are expected to begin trading on The Nasdaq Capital Market on Tuesday, December 23, 2014 under the ticker symbol "CTSO".
CTSO: 8.20 (+0.18)
CytoSorbents Announces Strategic Partnership with Fresenius Medical Care
PR Newswire Europe - Tue Dec 16, 2:28AM CST
CytoSorbents Corporation (OTCQB: CTSOD), a leader in critical care immunotherapy and blood purification, announced yesterday that they have entered into a multi-country strategic partnership with Fresenius Medical Care AG & CO KGaA to commercialize CytoSorbents' CytoSorb(R) therapy.
Recent CytoSorb® Case Reports Highlight its Use to Help Save the Lives of Critically-Ill Patients
PR Newswire - Wed Dec 10, 8:25AM CST
CytoSorbents Corporation (OTCQB: CTSO) trading under stock ticker symbol CTSOD, a critical care immunotherapy company commercializing its CytoSorb® cytokine adsorber to treat deadly inflammation in critically-ill patients, highlights recent treatment successes published in peer-reviewed journal articles.
CTSO: 8.20 (+0.18)
/C O R R E C T I O N -- CytoSorbents Corporation/
PR Newswire - Fri Dec 05, 2:37PM CST
In the news release, "CytoSorbents Teams with Smart Medical Solutions to Distribute CytoSorb in Romania and Moldova", issued 05-Dec-2014 by CytoSorbents Corporation over PR Newswire, we are advised by the Company that the common stock trading symbol of CytoSorbents Corporation has temporarily changed for the next 20 trading days to "CTSOD" to reflect the reverse split of the Company's common shares that became effective on December 4, 2014, after which it will revert back to "CTSO". The new CUSIP number is 23283X 206. The shares will continue to trade on the OTCQB, although the Company has disclosed that it has filed an application to up-list to the NASDAQ Capital Markets which is pending final evaluation. According to the Company, there can be no assurances that NASDAQ will approve this application. The complete, corrected release follows:
CTSO: 8.20 (+0.18)
